ANTITUMORAL TERPENOID PHARMACEUTICAL COMPOSITION 'ABISILIN' EXHIBITING ANGIOGENESIS-INHIBITING ACTION

摘要

The invention relates to medicine and chemical and pharmaceutical industry, and concerns to a pharmaceutical for treating diseases associated with angiogenesis disorders, in particular, to a method for treating oncological diseases of various geneses, by means of inducing angiogenesis inhibition adjuvant to the direct antitumor, anti-recurrent, and antimetastatic effect, as well as the associated activation of endogenous apoptosis. The invention is accomplished by use of a new oral dosage form Abisilin containing, as ingredients, natural terpene compounds (isoprenoids) derived from coniferous trees of the Pinaceae family, this dosage form comprising: sesquiterpenoids (3 to 6%); neutral terpenoids (11 to 15%); diterpene acids (23 to 28%); triterpene acids (8 to 16%); unsaturated and saturated fatty acids (0.1 to 0.3%); phenolic compounds (0.1 to 0.2%); monoterpenoids being the rest, wherein the bornyl acetate content is at least 10.0% relative to the total terpenes composition. The use of the new oral dosage form Abisilin, the substances whereof are known to exhibit immunomodulatory, antibacterial, anti-inflammatory, pain-releasing, wound-healing, and other pharmacologically significant effects; which lacks counter-indications or toxic effects; and which is suitable for use together with various agents in a complex therapy, is intended to provide a new therapeutic approach and to enhance the efficiency of treating oncologic and many other diseases associated with angiogenesis disorders.